Type 2 Diabetes

Polycystic ovary syndrome, a common endocrine disorder affecting reproductive-age women, is linked to cardiometabolic disorders that are risk factors for CVD. But the degree of CVD risk in women with polycystic ovary syndrome is still underdetermined.

ATLANTA — Testosterone undecanoate therapy is associated with improved quality of life and reduced symptom severity in men with hypogonadism and type 2 diabetes, according to data presented at ENDO 2022.

ATLANTA — Use of empagliflozin was associated with a nearly 40% reduced risk for nephrolithiasis among people with type 2 diabetes, according to data presented at ENDO 2022.

ATLANTA — Adults with type 2 diabetes who were prescribed insulin had greater risks for major osteoporotic and hip fractures than those prescribed metformin, according to study data.

ATLANTA — In patients who recently developed gestational diabetes, addressing stress and associated postpartum depressive symptoms early may reduce the risk for developing type 2 diabetes, researchers said.

NEW ORLEANS — In the third part of this video exclusive, James R. Gavin III, MD, PhD, talks with Jamy D. Ard, MD, about new drugs for substantial weight loss and treatment of obesity-related comorbidities, including type 2 diabetes and liver disease.

NEW ORLEANS — There is no single answer when it comes to determining the primary target for treating type 2 diabetes, two speakers said during a debate at the American Diabetes Association Scientific Sessions.

NEW ORLEANS — A novel “counterintuitive” intervention that reduces glucokinase activity and limits the buildup of metabolites may enhance insulin secretion and ultimately prevent or even reverse type 2 diabetes, according to a speaker.

NEW ORLEANS — An intervention program powered by artificial intelligence and data collected by sensors was linked to a type 2 diabetes remission rate of more than 80%, according to a presenter.

NEW ORLEANS — Young people with type 2 diabetes taking the once-weekly GLP-1 receptor agonist dulaglutide had a decrease in HbA1c at 26 weeks without a significant change in BMI, according to findings from a phase 3 trial.